Drug Trial Radar · NCT04722146
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
140
Actual
Start
Mar 12, 2021
Primary completion
Oct 3, 2025
Study completion Oct 13, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Conditions
- Multiple Myeloma
Interventions
TeclistamabDrug
Participants will receive teclistamab.
DaratumumabDrug
Participants will receive daratumumab.
PomalidomideDrug
Participants will receive pomalidomide.
LenalidomideDrug
Participants will receive lenalidomide.
BortezomibDrug
Participants will receive bortezomib.
NirogacestatDrug
Participants will receive nirogacestat.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Incidence of Adverse Events (AEs)Time frame: Up to 2 year and 5 months
- Number of Participants with AEs by SeverityTime frame: Up to 2 year and 5 months
- Number of Participants with Abnormalities in Laboratory ValuesTime frame: Up to 2 year and 5 months
- Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: Up to Cycle 2 Day 21 (each cycle is of 28 days for Treatment Regimen A and 21 days for Treatment Regimen B)
Locations
27 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California San Francisco
San Francisco, California
Colorado Blood Cancer Institute
Denver, Colorado
Winship Cancer Institute Emory University
Atlanta, Georgia
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Washington University School Of Medicine
St Louis, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center
New York, New York
Weill Cornell Medical College
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Tennessee Oncology
Nashville, Tennessee
Fred Hutchinson Cancer Center
Seattle, Washington
Medical College Of Wisconsin
Milwaukee, Wisconsin
St Vincents Hospital Melbourne
Fitzroy, Australia
Alfred Health
Melbourne, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
UZA
Edegem, Belgium
UZ Gent
Ghent, Belgium
Centre Leon Berard
Lyon, France
CHU Nantes
Nantes, France
CHU de Bordeaux - Hospital Haut-Leveque
Pessac, France
Chu Rennes Hopital Pontchaillou
Rennes, France
Institut Universitaire du cancer de Toulouse-Oncopole
Toulouse, France
University College Hospital
London, United Kingdom
The Christie Nhs Foundation Trust
Manchester, United Kingdom
The Royal Marsden NHS Trust Sutton
Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.